Multicentre randomised double-blinded placebo-controlled trial of favipiravir in adults with mild COVID-19

INTRODUCTION: A novel coronavirus, designated SARS-CoV-2, caused an international outbreak of a respiratory illness, termed COVID-19 in December 2019. There is a lack of specific therapeutic agents based on evidence for this novel coronavirus infection; however, several medications have been evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales: Bosaeed, Mohammad, Alharbi, Ahmad, Hussein, Mohammad, Abalkhail, Mohammed, Sultana, Khizra, Musattat, Abrar, Alqahtani, Hajar, Alshamrani, Majid, Mahmoud, Ebrahim, Alothman, Adel, Alsaedy, Abdulrahman, Aldibasi, Omar, Alhagan, Khalid, Asiri, Abdullah Mohammed, AlJohani, Sameera, Al-Jeraisy, Majed, Alaskar, Ahmed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Infectious Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053307/
https://www.ncbi.nlm.nih.gov/pubmed/33853806
http://dx.doi.org/10.1136/bmjopen-2020-047495

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053307/
https://www.ncbi.nlm.nih.gov/pubmed/33853806
http://dx.doi.org/10.1136/bmjopen-2020-047495

Ejemplares similares